Search research articles

Search research articles

Related Experiment Videos

Experimental design constraints on carcinogenic potency estimates.

J P Rieth¹, T B Starr

¹Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina 27709.

Journal of Toxicology and Environmental Health

|January 1, 1989

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study.

Critical reviews in toxicology·2013

Same author

A meta-analysis of cohort studies describing mortality and cancer incidence among chemical workers in the United States and western Europe.

Epidemiology (Cambridge, Mass.)·2001

Same author

Significant shortcomings of the U.S. Environmental Protection Agency's latest draft risk characterization for dioxin-like compounds.

Toxicological sciences : an official journal of the Society of Toxicology·2001

Same author

Mode-of-action-based dosimeters for interspecies extrapolation of vinyl acetate inhalation risk.

Inhalation toxicology·2001

Same author

Reevaluation of the cancer potency factor of toxaphene: recommendations from a peer review panel.

Toxicological sciences : an official journal of the Society of Toxicology·2000

Same author

"Comparison of aldicarb and methamidophos neurotixicity at different ages in the rat: behavioral and biochemical parameters".

Toxicology and applied pharmacology·2000

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Chronic rodent bioassays, used for estimating chemical carcinogenic potency (beta), are limited by fixed dose levels and sample sizes. These constraints restrict the accuracy of multistage model analyses, making bioassays inadequate for human risk assessment.

Area of Science:

Toxicology and Carcinogenesis
Risk Assessment
Regulatory Science

Background:

U.S. regulatory agencies utilize the multistage model to estimate chemical carcinogenic potency (beta).
Data for these estimates are primarily derived from chronic rodent bioassays.
Key variables in bioassays include dose level, sample size, and response incidence.

Purpose of the Study:

To evaluate the limitations of chronic rodent bioassays in estimating carcinogenic potency.
To assess the adequacy of current bioassay designs for human risk assessment.
To determine the impact of experimental design constraints on multistage model analyses.

Main Methods:

Analysis of experimental design constraints in typical National Toxicology Program (NTP) bioassays.

Related Experiment Videos

Calculation of maximum possible finite potency estimates from existing bioassay data for 82 mouse carcinogens.

Comparison of potency estimates with the inverse maximum dose tested.

Main Results:

Conventional bioassay protocols fix dose levels (e.g., maximum tolerated dose [MTD] and fractions) and sample sizes (typically 50 animals).
These constraints limit the multistage model's practical variability to the incidence of treatment-related response.
Maximum potency estimates were generally within one order of magnitude of the inverse maximum dose tested.

Conclusions:

The fixed experimental design of chronic rodent bioassays significantly constrains carcinogenic potency estimation.
The multistage model, in practice, relies heavily on response incidence, with limited input from dose and sample size.
Chronic rodent bioassays alone are insufficient for accurately estimating human carcinogenic risk from chemical exposure.